根据公告，股东苏州元生私募基金管理合伙企业（有限合伙）-苏州工业园区新建元二期创业投资 企业（有限合伙）（以下简称"新建元"）拟合计减持公司股份不超过1,622,440股，减持比例不超过公司 股份总数的2.0000%。其中，通过集中竞价交易方式减持不超过811,220股，减持期间为本次减持股份计 划公告日起15个交易日后的90个自然日内；通过大宗交易方式减持不超过811,220股，减持期间为本次 减持计划公告日起3个交易日之后的90个自然日内。 公告称，在减持期间内，股东根据市场情况、公司股价等因素选择是否实施及如何实施减持计划， 减持时间、减持价格、减持数量等存在不确定性。本次减持计划系公司股东系自身资金需求进行的减 持，不会对公司治理结构、持续经营情况产生重大影响。本次减持计划不会导致上市公司控制权发生变 更。 2023年5月19日，安杰思在上交所科创板上市，发行价格为125.80元/股，发行股票数量1,447.0000 万股，保荐机构（主承销商）为中信证券股份有限公司，保荐代表人为徐峰、王鹏。目前该股处于破发 状态。 中国经济网北京3月20日讯 安杰思（688581.SH）昨日晚间披露《股东减持股份计划 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 证券代码：688581 证券简称：安杰思 公告编号：2026-010 杭州安杰思医学科技股份有限公司 股东减持股份计划公告 截止本公告披露日，公司股东苏州元生私募基金管理合伙企业（有限合伙） －苏州工业园区新建元二期创业投资企业（有限合伙）（以下简称"新建元"）持 有杭州安杰思医学科技股份有限公司（以下简称"安杰思医学"或"公司"）股份 2,888,019 股，占公司总股本的 3.5601%，其中持有的股份来源为公司首发前股份 数 2,062,871 股，通过公司 2023 年年度派送红股获得的股份数 825,148 股。新建 元持有的公司首发前股份已于 2024 年 5 月 20 日解除限售并上市流通。 减持计划的主要内容 因企业自身的经营安排，股东新建元拟合计减持公司股份不超过 1,622,440 股（即不超过公司股份总数的 2.0000 %），其中，通过集中竞价交易方式减持不 超过 811,220 股；通过大宗交易方式减持 ...

证券代码：688581 证券简称：安杰思 公告编号：2026-009 杭州安杰思医学科技股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金 额 | 实际为其提供的 担保余额（不含本 | 是否在前期预 计额度内 | 本次担保是否 有反担保 | | --- | --- | --- | --- | --- | | | | 次担保金额） | | | | 杭安医学科技（杭 | 2,000.00 万元 | 0.00 万元 | 是 | 否 | | 州）有限公司 | | | | | | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公 | 2,000.00 | | 司对外担保总额（万元） | | | 对外担保总额占上市公司最近一期经 审计净资产的比例（%） | 0.83% | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一期经审 计净资产 5 ...

证券代码：688581 证券简称：安杰思 公告编号：2026-008 杭州安杰思医学科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、投资情况概述 （四）投资期限 （一）投资目的 为提高公司资金使用效率，增加股东回报，在确保不影响公司正常经营和主 营业务发展的前提下，公司使用闲置自有资金购买银行等金融机构理财产品，可 在一定程度上实现公司现金的保值及增值，为公司及股东获取更多回报。 （二）投资额度 1 据公司当前的资金使用状况，拟使用不超过人民币12亿元的闲置自有资金进 行现金管理，授权期限自公司董事会审议通过之日起12个月内有效。单个投资产 品的投资期限不超过一年。在上述额度和期限内，资金可以循环滚动使用。 （五）资金来源 杭州安杰思医学科技股份有限公司（以下简称"公司"）拟使用不超过人民 币12亿元的闲置自有资金进行现金管理，购买安全性高、流动性好的产品， 包括但不限于银行、证券公司、保险公司、信托公司、资产管理公司、基金 公司等专业理财机 ...

Core Viewpoint - Antili reported a decline in revenue and net profit for the year 2025, marking the first year-on-year decrease in net profit since its listing in 2023 [1][3]. Financial Performance - The total operating revenue for 2025 was 597.21 million yuan, a decrease of 6.19% compared to the previous year [1][2]. - The net profit attributable to the parent company was 222.82 million yuan, down 24.06% year-on-year [1][2]. - The net profit after deducting non-recurring gains and losses was 191.42 million yuan, reflecting a decline of 29.81% from the previous year [1][2]. - Basic earnings per share were 2.77 yuan, a decrease of 23.90% compared to the previous year [2]. - The weighted average return on net assets was 9.08%, down 3.72 percentage points from the previous year [2]. Asset and Equity Growth - As of the end of the reporting period, total assets amounted to 2,674.01 million yuan, an increase of 4.87% from the beginning of the period [3]. - The equity attributable to the parent company was 2,515.85 million yuan, up 4.95% from the beginning of the period [3]. Shareholder Actions - In 2025, there were multiple instances of shareholder reductions, including a significant "clearing-style" reduction by shareholder Tiantang Silicon Valley [3]. - On May 13, 2025, Tiantang Silicon Valley reduced its holdings by 1,214,483 shares, accounting for 1.4998% of the total share capital [3]. - On September 11, 2025, Tiantang Silicon Valley further reduced its holdings by a total of 1,622,700 shares, representing 2.0039% of the total share capital [3]. - On October 23, 2025, shareholder Xinjian Yuan reduced its holdings by 345,816 shares, accounting for 0.4270% of the total share capital [4]. Company Overview - Antili, established in 2010, focuses on the design and development of products and surgical solutions in the field of minimally invasive interventional therapy, operating as a national high-tech enterprise [4].

Core Viewpoint - Anjias Medical Technology Co., Ltd. reported its first net loss since its IPO, primarily due to pressures from centralized procurement and tariff policies affecting the medical device industry [1][3]. Financial Performance - The company achieved total operating revenue of 597.21 million yuan, a decrease of 6.19% compared to the same period last year [2]. - The net profit attributable to the parent company was 222.82 million yuan, down 24.06% year-on-year [2]. - The net profit excluding non-recurring gains and losses was 191.42 million yuan, reflecting a decline of 29.81% compared to the previous year [2]. - Basic earnings per share decreased by 23.90% to 2.77 yuan [2]. - The weighted average return on net assets fell by 3.72 percentage points to 9.08% [2]. Financial Position - As of the end of the reporting period, total assets amounted to 2.67 billion yuan, an increase of 4.87% from the beginning of the period [2]. - The equity attributable to the parent company was 2.52 billion yuan, up 4.95% from the start of the period [2]. - The company's net asset per share increased by 4.27% to 31.02 yuan [2]. Industry Context - The medical device industry faced challenges due to domestic centralized procurement and overseas tariff policies, which intensified competition in the minimally invasive endoscopic treatment sector [3]. - The company maintained high levels of investment in R&D, production line updates, and domestic and international market operations, which impacted current profits [3]. Shareholder Activity - The company experienced multiple instances of shareholder reductions in 2025, with significant share sales by major shareholders [5][6]. - Notably, shareholder Tiantang Silicon Valley executed a "clearance-style" reduction, selling a total of 1.62 million shares, representing 2.0039% of the total share capital [5]. Market Performance - As of February 26, the company's stock price increased by 0.15% to 61.31 yuan per share, with a total market capitalization of 4.974 billion yuan [7].

Core Viewpoint - Anjiesi reported a decline in revenue and net profit for the fiscal year 2025, attributed to industry challenges and increased competition in the minimally invasive endoscopic treatment sector [1] Financial Performance - The company achieved total operating revenue of 597 million yuan in 2025, representing a year-on-year decrease of 6.19% [1] - The net profit attributable to shareholders was 223 million yuan, reflecting a year-on-year decline of 24.06% [1] Industry Context - The medical device industry faced pressures from domestic centralized procurement policies and overseas tariff regulations, impacting the company's main business [1] - Increased competition in the minimally invasive treatment field contributed to the company's performance challenges in 2025 [1]

Group 1 - The company Anjisi announced that it expects to achieve total operating revenue of 597.21 million yuan in 2025, representing a year-on-year decrease of 6.19% [2] - The net profit attributable to the parent company's owners is projected to be 222.82 million yuan, reflecting a year-on-year decline of 24.06% [2]

证券代码：688581 证券简称：安杰思 公告编号：2026-007 杭州安杰思医学科技股份有限公司 关于签署募集资金专户存储四方及五方监管协议的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 一、募集资金基本情况 | 序 | 开户主体 | 开户银行 | 专户账户 | 初始存储 资金（万 | 募投项 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 元） | 目名称 | | | 新加坡安杰思 | 中国工商银行 | | | | | 1 | 医学科技有限 | 股份有限公司 | NRA1202054229900094158 | | 安杰思 0 | | | 公司 | 杭州良渚支行 | | | 泰国生 | | | 安杰思医学科 | 中国工商银行 | 5100306338 | 0 | 产基地 | | 2 | 技（泰国）有 | （泰国）股份有 | | | 项目 | | | | | 5100306346 | 0 | | | | 限公司 | 限公司 | | | | 本次募集资金 ...

Core Viewpoint - Anjias (688581.SH) reported a decline in revenue and net profit for the fiscal year 2025, primarily due to industry challenges such as domestic medical insurance procurement policies and increased competition in the minimally invasive endoscopic treatment sector [1][2]. Group 1: Financial Performance - The company achieved total operating revenue of 597 million yuan, a decrease of 6.19% compared to the same period last year [1]. - The net profit attributable to the parent company was 223 million yuan, down 24.06% year-on-year [1]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 191 million yuan, reflecting a decline of 29.81% compared to the previous year [1]. Group 2: Industry Challenges - The medical device industry faced significant challenges due to domestic medical insurance centralized procurement and overseas tariff policies, impacting the company's performance [1]. - Increased competition in the minimally invasive endoscopic treatment field has also contributed to the pressure on the company's financial results [1]. Group 3: Strategic Initiatives - The company remains focused on research and innovation in minimally invasive endoscopic treatment devices and high-end diagnostic equipment, aiming to enhance product coverage [2]. - Investments in automation production lines have been increased to maintain stable gross margins and improve market competitiveness [2]. - The company is executing a globalization strategy, enhancing local operations in the Netherlands and developing a production base in Thailand, while also deepening channel management and exploring emerging markets [2]. - Significant investments have been made in multiple research and development pipelines, supporting a dual-driven development strategy for diagnostic equipment and medical devices, laying a solid foundation for business growth in 2026 [2].